Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

107.20 -0.43 (-0.40%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,222,632
Open 107.15
Bid (Size) 107.20 (1)
Ask (Size) 108.00 (20)
Prev. Close 107.63
Today's Range 106.42 - 107.87
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 1.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political

Performance

YTD
+4.98%
+4.98%
1 Month
-8.38%
-8.38%
3 Month
-19.68%
-19.68%
6 Month
-16.52%
-16.52%
1 Year
+7.17%
+7.17%

More News

Read More
Investors Like Certainty. Trump's Win Gave Them Some.
Via The Motley Fool
Topics Government
Exposures Political
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Via Benzinga
Topics Death
Exposures Death Product Safety
Novo Nordisk Aims For The Top: CagriSema Poised For Breakthrough
Via Talk Markets
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Via Benzinga
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
Via Benzinga
Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Via Benzinga
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Via Investor's Business Daily
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Via Benzinga
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
Via Investor's Business Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Via The Motley Fool
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Via MarketBeat
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.